Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + docetaxel + lobaplatin + nab-paclitaxel
- Development stage
- Preclinical
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of anlotinib (a multi-target tyrosine kinase inhibitor that inhibits angiogenesis-related kinases such as VEGFR, FGFR, PDGFR, and c-Kit), docetaxel (a taxane chemotherapy agent), lobaplatin (a platinum-based chemotherapy agent), and nab-paclitaxel (an albumin-bound formulation of paclitaxel). While clinical data exists for anlotinib plus docetaxel in non-small cell lung cancer (NSCLC), showing improved progression-free survival compared to docetaxel alone, specific information about the four-drug combination is not available in the provided search results.
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on anlotinib + docetaxel + lobaplatin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + docetaxel + lobaplatin + nab-paclitaxel.